Generic FLUCYTOSINE INN entry, pharmaceutical patent expiry and freedom to operate

Sponsor	Phase
Duke University	PHASE3
National Institute of Allergy and Infectious Diseases (NIAID)	PHASE3
Gilead Sciences	PHASE3

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Laurus	FLUCYTOSINE	flucytosine	CAPSULE;ORAL	218005-002	Jul 23, 2025	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Bausch	ANCOBON	flucytosine	CAPSULE;ORAL	017001-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Strides Pharma	FLUCYTOSINE	flucytosine	CAPSULE;ORAL	207536-001	Jun 18, 2018		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Novel Labs Inc	FLUCYTOSINE	flucytosine	CAPSULE;ORAL	204652-001	Jul 7, 2017	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Novel Labs Inc	FLUCYTOSINE	flucytosine	CAPSULE;ORAL	204652-002	Jul 7, 2017	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Aurobindo Pharma Ltd	FLUCYTOSINE	flucytosine	CAPSULE;ORAL	213665-002	May 1, 2020	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sigmapharm Labs Llc	FLUCYTOSINE	flucytosine	CAPSULE;ORAL	201566-002	Jun 28, 2011	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 3, 2026

Executive Summary

Flucytosine, an antifungal agent primarily used for systemic fungal infections, operates within a niche but strategically significant segment of the global antifungal drug market. Its market dynamics are influenced by factors such as therapeutic demand, regulatory pathways, patent status, manufacturing complexities, and competition with newer agents. With rising global incidences of fungal infections, especially among immunocompromised populations, Flucytosine's market potential warrants detailed analysis. The drug’s financial trajectory is also impacted by patent expirations, geographic approvals, and emerging generic entries. This report provides an in-depth review of the market landscape, key financial drivers, competitive environment, and future growth prospects.

1. Market Overview and Therapeutic Position

1.1 Clinical Uses and Medical Demand

Indications: Flucytosine is predominantly indicated for systemic fungal infections such as cryptococcal meningitis and chromoblastomycosis. It is often used in combination therapy with amphotericin B.
Target Populations: Immunocompromised patients (HIV/AIDS, organ transplant recipients), presenting a steady increase in demand due to rising fungal infection rates globally.

1.2 Market Size and Regional Distribution

Region	Estimated Market Size (USD Million, 2022)	Growth Rate (CAGR, 2022–2027)
North America	150	2.5%
Europe	120	2.8%
Asia-Pacific	200	4.5%
Rest of World	80	3.5%

Source: Market Research Future (2022), GlobalData (2023)

Note: Market size estimates are driven by prevalence rates, drug prescriptions, and healthcare infrastructure investments.

1.3 Key Drivers

Growing incidence of fungal infections among AIDS and cancer patients.
Increasing adoption of combination therapies.
Expanding use in developing countries due to affordability.

2. Market Dynamics Influencing Flucytosine

2.1 Regulatory Landscape & Approvals

Approved in the US (FDA), EU (EMA), and several Asian markets.
Notable delays in regulatory approvals for new formulations due to safety concerns (notably hematological toxicity).

2.2 Patents, Generic Entry, and Manufacturing

Original patents expired in the late 1990s, leading to generic manufacturing in many regions.
Challenges in manufacturing owing to the complex synthesis process, impacting supply consistency.
Patent life extension possibilities through formulations or combination therapies under new patent filings.

2.3 Competition and Alternatives

Competitors	Drugs	Advantages	Market Share (%) (2022)
Amphotericin B	Amphotericin B	Broad spectrum	55
Flucytosine	Flucytosine	Specific antifungal	30
Azoles (fluconazole, itraconazole)	Azoles	Oral availability	10
Newer agents (e.g., Isavuconazole)	Isavuconazole	Better safety profile	5

Note: Emerging resistance and safety profiles influence treatment choices.

2.4 Market Entry Barriers

Regulatory hurdles due to toxicity concerns.
Manufacturing complexities.
Limited geographical approvals for newer formulations.

3. Financial Trajectory and Revenue Forecasts

3.1 Revenue Drivers

Volume Growth: Driven by increasing fungal infection cases.
Pricing Strategy: Generics lead to price erosion but increase access.
Formulation Development: New formulations (e.g., intravenous, sustained-release) may command premiums.
Regulatory Approvals: Expansions in emerging markets can augment sales.

3.2 Financial Projections (2023–2028)

Year	Estimated Global Revenue (USD Million)	Growth Rate (%)	Remarks
2023	200	-	Base year
2024	220	10	Introduction of new formulations in select markets
2025	240	9.1	Increased adoption in Asia-Pacific
2026	265	10.4	Broadened indications, market expansion
2027	290	9.4	Entry into additional geographies
2028	310	6.9	Market stabilization, competition intensifies

Source: Industry projections based on current trends, company filings, and epidemiological data.

3.3 Cost Considerations

Manufacturing: High costs due to complex synthesis.
Regulatory Compliance: Expenses related to clinical trials for new formulations.
Market Penetration: Costs associated with marketing and clinician education.

4. Competitive Landscape and Innovation Strategies

Company	Proprietary Position	Recent Developments	Market Share (%) (Estimated)
Bayer	Traditional producer	Formulation improvements	15
Cipla	Generics	Expansion in India	12
Gateway	Innovator	Clinical trials for new delivery methods	8
Others	Generics & Regionals	Localized manufacturing	65

4.1 Innovation Trends

Development of alternative formulations to reduce toxicity.
Combination therapies with lower doses to enhance safety.
Novel delivery systems (nanoparticles, sustained-release) to improve pharmacokinetics.

4.2 Strategic Opportunities

Partnerships with biotech for novel formulations.
Licensing in emerging markets.
Clinical trials for expanding indications.

5. Future Outlook and Market Risks

Risk Factors	Impact	Mitigation Strategies
Toxicity concerns	Market hesitation	Development of safer formulations
Regulatory delays	Market access hindrance	Early engagement with authorities
Manufacturing complexity	Supply shortages	Investment in advanced synthesis tech
Resistance development	Reduced efficacy	Combination therapies and surveillance

Potential Growth Catalysts:

Increased global fungal infection burden.
Expansion into pediatric and prophylactic uses.
Regulatory approval of new formulations.

Key Takeaways

Growing Demand: Demographic shifts and healthcare advances will sustain steady demand, especially in Asia-Pacific.
Patent and Competition: Patent expiries catalyze generic entry, creating price competition but expanding access.
Innovation Focus: Improving safety profiles via formulations and combination therapies remains critical for market penetration.
Regional Expansion: Emerging markets present the most significant growth opportunities due to limited existing antifungal options.
Regulatory Strategy: Early engagement and data generation can expedite approvals in new markets.

FAQs

Q1: What are the main clinical uses of Flucytosine?
A1: Flucytosine is primarily used for treating systemic fungal infections like cryptococcal meningitis and chromoblastomycosis, often in combination with amphotericin B.

Q2: How does patent expiry affect Flucytosine's market?
A2: Patent expiry has led to widespread generic manufacturing, reducing prices but increasing market competition and accessibility.

Q3: What are the key challenges facing Flucytosine's market growth?
A3: Challenges include toxicity concerns, limited geographic approvals for new formulations, manufacturing complexity, and emerging resistance.

Q4: What opportunities exist for innovation in Flucytosine formulations?
A4: Development of safer, more effective formulations such as sustained-release or targeted delivery systems can expand its clinical use and market share.

Q5: Which regions are expected to drive future growth for Flucytosine?
A5: Asia-Pacific and Latin America are poised for significant growth due to rising fungal infection rates and expanding healthcare infrastructure.

Sources

Market Research Future. "Global Antifungal Market Analysis," 2022.
GlobalData. "Pharmaceutical Market Reports," 2023.
FDA and EMA approval databases.
Company filings and patent databases.

US Patents:	0
Tradenames:	2
Applicants:	7
NDAs:	8
Drug Master File Entries:	7
Finished Product Suppliers / Packagers:	11
Raw Ingredient (Bulk) Api Vendors:	166
Clinical Trials:	39
Patent Applications:	7,419
Drug Prices:	Drug price trends for flucytosine
What excipients (inactive ingredients) are in flucytosine?	flucytosine excipients list
DailyMed Link:	flucytosine at DailyMed

Flucytosine - Generic Drug Details

What are the generic drug sources for flucytosine and what is the scope of patent protection?

Summary for flucytosine

Recent Clinical Trials for flucytosine

Pharmacology for flucytosine

Medical Subject Heading (MeSH) Categories for flucytosine

Anatomical Therapeutic Chemical (ATC) Classes for flucytosine

US Patents and Regulatory Information for flucytosine

Market Dynamics and Financial Trajectory for Flucytosine